Nuvalent Q2 2025 net loss $99.7M; rolling NDA for zidesamtinib initiated

Nuvalent, Inc.

2025-Q2 EPS reported -$2.57

Net loss $99.7M; R&D $80.9M, G&A $23.7M; cash $1.0B funding into 2028.
Rolling NDA for zidesamtinib (ROS1+ NSCLC) initiated; target completion Q3 2025; FDA RTOR pilot.
ALKAZAR Phase 3 of neladalkib (ALK+ NSCLC) dosed; topline TKI pre-treated data expected year-end 2025.
Preliminary data for neladalkib in ALK+ solid tumors at ESMO 2025 (Oct 17-21).
Jason Waters promoted to SVP Commercial; Christy Oliger appointed to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.